Monday Jun 30
Pharmacyclics Receives Outperform Rating from Credit Suisse
's stock had its "outperform" rating restated by analysts at Credit Suisse in a research report issued to clients and investors on Monday.
The Motley Fool
Johnson & Johnson Scores a Solid Hit With Imbruvica
The biggest cancer conference of the year is over, and star talent Imbruvica one out of the ballpark for its Big Pharma part-owner, Johnson & Johnson , making it one of the highest-priced cancer drugs in recent memory.
Bob Duggan Innovating Medicine
Bob Duggan is again leading the way with innovation in the field of medicine. After pioneering the field of robotic surgery, he and his team at Pharmacyclics Inc. are now taking on cancer.
Idenix high premium bodes well for Achillion, says Leerink
Imbruvica shows durable, long-term responses for patients with CLL Pharmacyclics announced that IMBRUVICA, ibrutinib, will be featured in an oral presentation highlighting long-term responses to treatment, with up to three years of follow up in 132 patients with treatment naive or relapsed/refractory chronic lymphocytic leukemia or small ... (more)